z-logo
Premium
Prognostic Value of Le y and H Antigens in Oral Tongue Carcinomas
Author(s) -
Xie Xin,
Boysen Morten,
Clausen Ole Petter F.,
Bryne Magne A.
Publication year - 1999
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-199909000-00022
Subject(s) - antigen , tongue , immunohistochemistry , apoptosis , epitope , microbiology and biotechnology , pathology , tongue neoplasm , proliferating cell nuclear antigen , medicine , cancer research , biology , immunology , biochemistry
Objective: To investigate the prognostic significance of the carbohydrate epitopes H and Le y and their relationship with proliferation and apoptosis. Study Design: Eighty randomly selected patients with T1‐T4 oral tongue squamous cell carcinoma (SCC) were studied. Serial sections were cut from diagnostic, formalin‐fixed, paraffin‐embedded specimens. Methods: Sections were stained immunohistochemically for H antigen and Le y . Results: Expression of H antigen was associated positively with Le y expression ( P = .0001). Expressions of H antigen or Le y correlated with the proliferative markers Ki67 ( P = .0442 and P = .0003, respectively) and pAgNOR >1 ( P = .0674 and P = .0047, respectively), but not with apoptotic markers such as Bax expression or the apoptotic index (AI). Tumors that expressed H antigen and high levels of Le y (>50%) had a poor prognosis ( P = .0006 and P = .0056, respectively). Combinations of expression of H antigen and Le y , and either proliferative or apoptotic markers revealed an enhanced prognostic potential ( P < .0001). The combination of pAgNOR score greater than 1 and H‐antigen expression appeared to be the best combination to predict good prognosis. Conclusion: The expression of H antigen and Le y , especially their combination with proliferative or apoptotic markers, has prognostic value in tongue SCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here